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Just before the publication of this issue of “Cli-
nical Diabetology”, the largest diabetes meeting in 
the world — 79th Scientific Sessions of the American 
Diabetes Association (ADA) — was held on June 7–11, 
2019 in San Francisco, USA. During this congress, all 
clinical and scientific aspects of diabetes were raised 
in countless lectures, oral presentations and poster 
sessions. It is impossible to mention all of them, but 
I would like to draw your attention to the reports of 
the greatest interest of the congress participants. These 
were the reports presenting detailed analysis of the 
results of large clinical trials, such as PIONEER, REWIND, 
DECLARE-TIMI 58, CREDENCE, CAROLINA, assessing 
potential cardio- and nephroprotective effects of new 
classes of antidiabetic drugs, such as SGLT2 inhibitors 
or GLP1 analogs, as well as the cardiovascular and re-
nal safety of linagliptin compared with a sulfonylurea. 
Thanks to these trials we now know for certain that 
the drugs assessed are safe in terms of cardiovascular 
and renal function in different patient populations. In 
addition, the analysis of the results of the CREDENCE 
study with canagliflozin, for the first time since the 
proven nephroprotective effect of RAA blockers, ACE 
inhibitors and sartans, proved that this is another 
nephroprotective drug for diabetic patients. Soon, we 
will also learn about the results of the trials assessing 
kidney function in patients treated with two other 
SGLT2 inhibitors, dapagliflozin and empagliflozin, 
which are also expected to confirm the class effect in 
this respect. This would allow the indications for their 
use in everyday practice to be extended. In addition, 
the results of the DECLARE-TIMI 58 trial showed that 
dapagliflozin therapy is associated with benefits in 
primary prevention of heart failure in diabetes, a com-
plication that until recently was underestimated and 
now is considered as one of the major challenges of 
modern medicine due to the increasing number of 
affected patients.
It should also be stressed here that this issue is 
being released in convergence with the next, large and 
very important scientific meeting of our community 
— the 20th Scientific Congress of Diabetes Poland that 
this year was held on May 16–18, in Lublin. During this 
meeting, apart from the very high scientific level, there 
was also space for interesting cultural events.
Among papers included in this issue of “Clinical 
Diabetology”, there is a particularly interesting paper 
by the authors from Egypt who discuss the correlations 
between microangiopathic complications in type 2 dia-
betes. Another article that is worth mentioning is the 
article about the DAWN (Diabetes Attitudes, Wishes and 
Needs) study. This article does not address the most fre-
quently discussed aspects of organic complications in 
diabetes but focuses on the mental sphere of patients.
This very issue of “Clinical Diabetology” is special 
to me because this is my last issue as Editor-in-Chief. 
Managing “Clinical Diabetology” was a great adventu-
re to me and now I am handing over the helm to the 
person who guarantees the further development of our 
journal, and, what I deeply believe, will soon introduce 
“Clinical Diabetology” into the PubMed and MEDLINE 
databases and then into a list of journals indexed in 
the ISI databases, Master Journal List, known in Po-
land as the Philadelphia List. The next Editor-in-Chief, 
appointed to this honorable position by the newly 
elected Main Board of Diabetes Poland, is Professor 
Leszek Czupryniak.
As usual, I would like to thank all the authors 
for submitting so many interesting manuscripts and 
I encourage you to further cooperation with the new 
Editor-in-Chief of “Clinical Diabetology”, a journal that 
is constantly growing thanks to your support.
Editor-in-Chief
Prof. Janusz Gumprecht
Dear Colleagues,
